Table 1 Patient characteristics by... | American Society of Hematology

Table 1

Patient characteristics by randomized treatment group

	No G-CSF		G-CSF
	No.	%	No.	%
All patients	156	100.0	161	100.0
Sex, male/female	72/84*	46.2/53.8	96/65*	59.6/40.4
Age
Younger than 1 y	41	26.3	56	34.8
1-9 y	47	30.1	52	32.3
10 y or older	68	43.6	53	32.9
Leukocytes
Less than 20 × 10³/μL	100	64.1	87	54.0
Between 20 and less than 100 × 10³/μL	37	23.7	44	27.3
100 × 10³/μL or more	19	12.2	30	18.6
CNS leukemia	12	7.7†	19	11.8†
FAB types
M0	8	5.1	8	5.0
M1	25	16.0	18	11.2
M1 with Auer	14	9.0†	8	5.0†
M2	39	25.0	41	25.5
M2 with Auer	28	17.9†	36	22.4†
M4	31	19.9	26	16.2
M4eo	14	9.0	17	10.6
M5	23	14.7	30	18.6
M6	7	4.5	4	2.5
M7	23	14.7	34	21.1
Other	1	0.6	0	0
Karyotypes and cytogenetics
Favorable‡	32	20.5†	32	19.9†
Other	102	65.4†	106	65.8†
Down syndrome	18	11.5	27	16.8
Standard risk	63	40.4	58	36.0
High risk	75	48.1	76	47.2

	No G-CSF		G-CSF
	No.	%	No.	%
All patients	156	100.0	161	100.0
Sex, male/female	72/84*	46.2/53.8	96/65*	59.6/40.4
Age
Younger than 1 y	41	26.3	56	34.8
1-9 y	47	30.1	52	32.3
10 y or older	68	43.6	53	32.9
Leukocytes
Less than 20 × 10³/μL	100	64.1	87	54.0
Between 20 and less than 100 × 10³/μL	37	23.7	44	27.3
100 × 10³/μL or more	19	12.2	30	18.6
CNS leukemia	12	7.7†	19	11.8†
FAB types
M0	8	5.1	8	5.0
M1	25	16.0	18	11.2
M1 with Auer	14	9.0†	8	5.0†
M2	39	25.0	41	25.5
M2 with Auer	28	17.9†	36	22.4†
M4	31	19.9	26	16.2
M4eo	14	9.0	17	10.6
M5	23	14.7	30	18.6
M6	7	4.5	4	2.5
M7	23	14.7	34	21.1
Other	1	0.6	0	0
Karyotypes and cytogenetics
Favorable‡	32	20.5†	32	19.9†
Other	102	65.4†	106	65.8†
Down syndrome	18	11.5	27	16.8
Standard risk	63	40.4	58	36.0
High risk	75	48.1	76	47.2

Significant difference between G-CSF and control group (P = .02).

Percentage of patients with data.

Definition of favorable cytogenetics: t(8;21), inv16.